Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain:The NVALT-9 Trial
- Brouns, Anita J. W. M.
- Hendriks, Lizza E. L.
- van Der Noort, Vincent
- van de Borne, Ben E. E. M.
- Schramel, Franz M. N. H.
- Groen, Harry J. M.
- Biesma, Bonne
- Smit, Hans J. M.
- Dingemans, Anne-Marie C.
Publication date
June 2020
DOIAbstract
Introduction:Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases have cancer induced bone pain (CIBP). Methods:The NVALT-9 was an open-label, single arm, phase II, multicenter study. Main inclusion criterion: bone metastasized NSCLC patients with uncontrolled CIBP [brief pain inventory [BPI] >= 5 over last 7 days]. Patients were treated with six milligram ibandronate intravenously (day 1-3) once a day. Main exclusion criteria: active secondary malignancy, systemic anti-tumor treatment and radiotherapy = 80% and 95% confidence to declare the treatment inactive if the pain response rate is</p
Add to ORKG